Den Europæiske Union - dansk - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykotika til systemisk brug - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - anidulafungin - candidiasis - antimykotika til systemisk brug - behandling af invasiv candidiasis hos voksne og pædiatriske patienter i alderen 1 måned til < 18 år.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

astellas pharma europe b.v. - micafungin - candidiasis - antimykotika til systemisk brug - mycamine er indiceret til:voksne, unge ≥ 16 år og elderlytreatment af invasiv candidiasis behandling af øsofagus candidiasis hos patienter, for hvem intravenøs behandling er hensigtsmæssig forebyggelse af candida infektioner hos patienter, der gennemgår allogen hæmatopoietisk stamcelle transplantation eller patienter, der forventes at få neutropeni (absolut neutrophil count < 500 celler/µl) for 10 eller flere dage. børn (herunder nyfødte) og unge < 16 år agetreatment af invasiv candidiasis. forebyggelse af candida infektioner hos patienter, der gennemgår allogen hæmatopoietisk stamcelle transplantation eller patienter, der forventes at få neutropeni (absolut neutrophil count < 500 celler/µl) for 10 eller flere dage. beslutningen om at bruge mycamine bør tage hensyn til en potentiel risiko for udvikling af tumorer i leveren. mycamine bør derfor kun anvendes, hvis andre antimykotika ikke er hensigtsmæssige.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - caspofunginacetat - candidiasis; aspergillosis - antimykotika til systemisk brug - behandling af invasiv candidiasis hos voksne eller pædiatriske patienter. behandling af invasiv aspergillose hos voksne eller pædiatriske patienter, som er refraktære over for eller intolerante over for amphotericin b, lipid formuleringer af amphotericin b og/eller itraconazol. uimodtagelighed over er defineret som progression af infektion eller manglende bedring efter minimum 7 dage før terapeutiske doser af effektiv svampedræbende terapi. empirisk behandling af formodede svampeinfektioner (såsom candida eller aspergillus) i febrile, neutropaenic voksne eller pædiatriske patienter.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

schering-plough europe - posaconazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimykotika til systemisk brug - posaconazol sp er indiceret til brug ved behandling af følgende svampeinfektioner hos voksne (se afsnit 5. 1):- invasiv aspergillose hos patienter med sygdom, der er refraktære over for amphotericin b eller itraconazol eller patienter, der ikke tåler disse lægemidler;- fusariosis hos patienter med sygdom, der er refraktære over for amphotericin b eller patienter, der er intolerante over for amphotericin b;- chromoblastomycosis og mycetoma hos patienter med sygdom, der er refraktære over for itraconazol eller patienter, der er intolerante over for itraconazol;- coccidioidomycosis hos patienter med sygdom, der er refraktære over for amphotericin b, itraconazol eller fluconazol eller patienter, der ikke tåler disse lægemidler.- oropharyngeale candidiasis: som første linje behandling til patienter, som har svær sygdom eller er immunsvækkede, i, som reaktion på aktuelle behandling forventes at være fattig. uimodtagelighed over er defineret som progression af infektion eller manglende bedring efter minimum 7 dage før terapeutiske doser af effektiv svampedræbende terapi. posaconazole sp er også indiceret til behandling af invasive svampeinfektioner i følgende patienter: patienter, der modtager syndernes forladelse-induktion kemoterapi for akut myeloid leukæmi (aml) eller myelodysplastisk syndrom (mds), der forventes at resultere i langvarig neutropeni og der areat høj risiko for at udvikle invasive svampeinfektioner;- hæmatopoietisk stamcelletransplantation (hsct) modtagere, der er under høj-dosis immunsuppressiv terapi for graft versus host-sygdom, og som er i høj risiko for udvikling af invasiv svampeinfektion.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

baxter a/s - alanin, arginin, calciumchloriddihydrat, dikaliumphosphat, glucosemonohydrat, glycin, histidin, isoleucin, leucin, lysinhydrochlorid, magnesiumchloridhexahydrat, methionin, natriumacetattrihydrat, natriumchlorid, phenylalanin, prolin, serin, threonin, tryptophan, tyrosin, valin - infusionsvæske, opløsning

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

baxter a/s - alanin, arginin, calciumchloriddihydrat, dikaliumphosphat, glucosemonohydrat, glycin, histidin, isoleucin, leucin, lysinhydrochlorid, magnesiumchloridhexahydrat, methionin, natriumacetat, natriumchlorid, phenylalanin, prolin, serin, threonin, tryptophan, tyrosin, valin - infusionsvæske, opløsning

Danmark - dansk - Ecolab

ecolab deutschland gmbh -

Den Europæiske Union - dansk - EMA (European Medicines Agency)

avimedical b.v. - itraconazol - antimykotika til systemisk brug, triazol-derivater, itraconazol - avian - til behandling af aspergillose og candidiasis i følgesvend fugle,.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

merck sharp and dohme b.v - posaconazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimykotika til systemisk brug - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 og 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. uimodtagelighed over er defineret som progression af infektion eller manglende bedring efter minimum 7 dage før terapeutiske doser af effektiv svampedræbende terapi. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 og 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 og 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. uimodtagelighed over er defineret som progression af infektion eller manglende bedring efter minimum 7 dage før terapeutiske doser af effektiv svampedræbende terapi. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 og 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. uimodtagelighed over er defineret som progression af infektion eller manglende bedring efter minimum 7 dage før terapeutiske doser af effektiv svampedræbende terapi. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invasiv aspergillose hos patienter med sygdom, der er refraktære over for amphotericin b eller itraconazol eller patienter, der ikke tåler disse lægemidler;- fusariosis hos patienter med sygdom, der er refraktære over for amphotericin b eller patienter, der er intolerante over for amphotericin b;- chromoblastomycosis og mycetoma hos patienter med sygdom, der er refraktære over for itraconazol eller patienter, der er intolerante over for itraconazol;- coccidioidomycosis hos patienter med sygdom, der er refraktære over for amphotericin b, itraconazol eller fluconazol eller patienter, der ikke tåler disse lægemidler.- oropharyngeale candidiasis: som første linje behandling til patienter, som har svær sygdom eller er immunsvækkede, i, som reaktion på aktuelle behandling forventes at være fattig. uimodtagelighed over er defineret som progression af infektion eller manglende bedring efter minimum 7 dage før terapeutiske doser af effektiv svampedræbende terapi. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.